

Review

Open Access

Selective Phosphodiesterase 4B Inhibitors: A Review

Mohammed Afzal AZAM *, Naga Srinivas TRIPURANENI

Department of Pharmaceutical Chemistry, J. S. S. College of Pharmacy, Ootacamund-643001, Tamil Nadu, India.

* Corresponding author. E-mail: afzal9azam@hotmail.com (M. A. Azam)

Sci Pharm. 2014; 82: 453–481

doi:10.3797/scipharm.1404-08

Published: June 10th 2014

Received: April 19th 2014

Accepted: June 10th 2014

This article is available from: <http://dx.doi.org/10.3797/scipharm.1404-08>

© Azam and Tripuraneni; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Phosphodiesterase 4B (PDE4B) is a member of the phosphodiesterase family of proteins that plays a critical role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP) by controlling its rate of degradation. It has been demonstrated that this isoform is involved in the orchestra of events which includes inflammation, schizophrenia, cancers, chronic obstructive pulmonary disease, contractility of the myocardium, and psoriatic arthritis. Phosphodiesterase 4B has constituted an interesting target for drug development. In recent years, a number of PDE4B inhibitors have been developed for their use as therapeutic agents. In this review, an up-to-date status of the inhibitors investigated for the inhibition of PDE4B has been given so that this rich source of structural information of presently known PDE4B inhibitors could be helpful in generating a selective and potent inhibitor of PDE4B.

Keywords

Phosphodiesterases (PDE) enzymes • Cyclic adenosine monophosphate • Selective PDE inhibitors • Chronic obstructive pulmonary disease • Antiproliferative activity • PDE4B

Introduction

Phosphodiesterases (PDEs) are a diverse family of enzymes involved in phosphoric diester hydrolytic cleavage. The term, however, is usually applied to phosphodiesterases that cleave cyclic nucleotides that are important for transmitting signals within the cell. These enzymes are known as cyclic nucleotide phosphodiesterases (PDEs). There are other families of phosphodiesterases, including phospholipases C and D, autotaxin,

sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases. Cyclic nucleotide PDEs constitute a superfamily of enzymes which catalyze the hydrolysis of 3',5'-cyclic adenosine monophosphate (cAMP) and 3',5'-cyclic guanosine monophosphate (cGMP) to their inactive 5'-AMP and 5'-GMP forms, respectively. In mammals, PDE enzymes are classified into 11 families, namely PDE1-PDE11. PDE4 is differentiated from other PDEs by its high sensitivity towards the inhibitors, and because of its potential use in the treatment of depression and schizophrenia [1, 2].

PDE4 is the major cAMP-metabolizing enzyme found in inflammatory and immune cells [3, 4]. The PDE4 family encompasses four genes coding the subtypes PDE4A, PDE4B, PDE4C, and PDE4D [5], but the PDE4B subtype is believed to play a central role in inflammation [6], being the predominant subtype in monocytes and neutrophils. All four PDE4 subtypes comprise a related structural organization with a highly conserved catalytic domain in the C-terminal region and upstream-conserved regions in the N-terminal portion of the protein [5]. The high-resolution structures of PDE4B complexes are presented and provide an insight into understanding the substrate and inhibitor binding as well as the critical function of metal ions [7, 8]. PDE4B comprises three domains: an N-terminal regulatory domain, a catalytic domain of about 300 amino acids, and a C-terminal domain. The catalytic domain is the most conserved domain among the PDE families and consists of 17 α -helices. Several reviews on PDE4 have appeared in articles [9–16] covering the role of phosphodiesterase-4 inhibitors in the treatment of asthma, chronic obstructive pulmonary, psoriasis, psoriatic arthritis, chronic inflammatory, autoimmune, and inflammatory bowel diseases. In this review, we present the most significant examples of PDE4B inhibitors that exhibit various biological activities reported in literature.

Selective PDE4B Inhibitors

The design of selective PDE inhibitors started in 1958 when Sutherland and Rall [17] identified the enzymatic activity of phosphodiesterases and its biochemical importance. These cyclic nucleotide levels play an important role in many mammalian physiologies ranging from immune and inflammatory responses [18], regulation of the contractility of the myocardium and smooth muscles [19], to depression and cognition [20]. These centric roles of cAMP initiated research efforts in developing selective inhibitors of PDEs such as vinpocetin for PDE1, inamrinone, milrinone, enaximone for PDE2, rolipram, cilomilast, roflumilast for PDE4, and sildenafil for PDE5 [21]. A pharmacological study in mice proved that PDE4B mediates antipsychotic effects [22, 23] by its role in dopamine-associated and stress-related processes. PDE4B is the only subtype of PDE4 expressed in the locus coeruleus, a region in the brain that is rich in nonadrenergic neurons that mediates some anti-depressant effects [24] and it is the only isoform of PDE4 expressed in the white matter of the brain. PDE4B is also involved in schizophrenia [25] and anxiety [26]. In contrast to PDE4B, PDE4D is expressed in the area postrema and nucleus of the solitary tract [27, 28], which are responsible for emesis.

The first generation the PDE4 inhibitor rolipram was withdrawn for its potent action on the PDE4D isoform, which is likely to be implicated in emesis [30]. PDE4B is abundant in inflammatory, immune, and airway smooth muscle cells [31] and thoroughly investigated for treating inflammatory pulmonary disorders [11]. Further, gene knockout studies proved that PDE4B could suppress TNF- α production [32] and has been investigated as an attractive and excellent therapeutic target due to its sensitivity to selective inhibitors

[33–35]. In the year 2004, a high throughput screening resulted in the identification of the lead compound **1a** (Figure 1), which exhibited significant PDE4B inhibition ($pIC_{50}6.8$) [36]. A high temperature reaction between N-1-ethyl-5-aminopyrazole and diethyl ethoxy-methylenemalonate resulted in the formation of the intermediate 4-hydroxypyrazolopyridine, which upon treatment with phosphoryl chloride gave the 4-chloro-derivative. Treatment of the 4-chloro-derivative with a diverse range of amines yielded **2a–g** (Figure 1) *via* thermal displacement [37]. Structure-activity data showed a significant increase in the potency with a branched or cycloalkyl amino group at fourth position of the pyridine nucleus, with 6-membered saturated rings being more potent than 5-membered rings. Tertiary amines such as pyrrolidine in **1c** and the N-methylated analogue such as **1e** were less tolerated and suggested the importance of the NH group. These observations were further supported by crystal structures of the pyrazolopyridine analogue **3a** (Figure 1) bound to PDE4B 152-503 (PDB ID: 3D3P), which showed the tetrahydropyran moiety towards the metal ions. An intramolecular hydrogen bond between the 4-amino NH group and the carbonyl of the amide was observed, which maintained the co-planarity with the template. Unbranched alkyl amines gave poor selectivity in comparison to the branched analogues, which routinely gave >100-fold selectivity.




Fig. 1. Structure of various congeners of pyrazolopyridine with PDE4B inhibitory activity

The structure-activity relationship is further exemplified by varying the substituent at first position of the pyrazolopyridine ring **2**. However, the simple alkyl and aryl substituent on first position did not yield selective PDE4B inhibitors, except for the hydroxyethyl substituent in the pyrazolopyridine derivative **2e**, which exhibited a similar pIC_{50} of 6.8 as that of the lead molecule. Introduction of the amide function at fifth position retained PDE4B selectivity and secondary amides were well-tolerated because of their lipophilic nature, while benzyl amide derivative **3a** and saturated analogues such as **3b** showed enhanced inhibitory activity on PDE4B with pIC_{50} values of 8.5 and 8.1, respectively. Primary amide **3c** showed significant inhibition (pIC_{50} 6.2), but tertiary amide **3d** and cyclic amide **3e** exhibited low inhibitory potential towards PDE4B with pIC_{50} values of 7.3 and 6.8, respectively.




Fig. 2. Analogues of 2-arylpyrimidines with PDE4B inhibitory activity

In the year 2009, 2-arylpyrimidine derivative **4a** (Figure 2) was identified as a selective and potent PDE4B inhibitor with an IC_{50} of sub-micromolar range ($0.19 \mu M$) and a potential 10-fold selectivity over PDE4D [38]. Authors further investigated the structure-activity relationship to optimize this lead compound which afforded a series of potent PDE4B inhibitors with >100-fold selectivity over the PDE4D isozyme. With a good pharmacokinetic

profile, the selected compound exhibited potent anti-inflammatory properties. The compounds bearing allyl (**4a**), ethyl (**4b**), cyano (**4c**), or formyl (**4d**) groups at fifth position of the pyrimidine ring were found to be equipotent for PDE4B inhibition (pIC_{50} 190, 140, 120, and 300 nM, respectively) and 4B/4D selectivity. Bulkier groups at this position reduced the potency in derivatives **4f** (PDE4B pIC_{50} 1300 nM), **4g**, **4h**, and **4j** (PDE4B pIC_{50} >1000 nM in all three compounds). Derivative **4k**, having an ethyl group at sixth position of the pyrimidine ring, showed enhanced potency (PDE4B pIC_{50} 34 nM), but less selectivity compared with the methyl analog **4a**. Authors also explored the SAR at second position of the pyrimidine ring. Potency and selectivity towards PDE4B was retained when the phenyl ring at second position of the pyrimidine ring was substituted with 2-thienyl **5a** (Figure 2) (PDE4B pIC_{50} 120 nM) or 3-thienyl **4b** (PDE4B pIC_{50} 68 nM) groups. However, substitution of thiazol-4-yl **5c** (PDE4B pIC_{50} 2800 nM), 2-pyridyl **5d** (PDE4B pIC_{50} 3700 nM), or pyridinyl **5e** (PDE4B pIC_{50} 860 nM) groups at the same position markedly reduced the potency. Similar results were observed when the phenyl ring was substituted at second position of the pyrimidine ring and a carboxymethyl group at fourth position of the aminophenyl moiety present at fourth position of the pyrimidine ring (**6a**) (Figure 2). However, compounds **6c** and **6d**, possessing a substituted thienyl group at R^1 and a carboxymethyl group at second position of pyrimidine ring, showed more than a 25-fold selectivity towards PDE4B. Further modification of the above compounds resulted in compounds **7a–d** (Figure 2), which showed potent inhibitory activity on PDE4B (pIC_{50} 15 nM, 6.8 nM, and 15 nM, respectively) and >100-fold selectivity over PDE4D (PDE4B pIC_{50} 1700 nM, 2900 nM, 3100 nM, respectively).




Fig. 3. Analogues of 3-aminocarboxy-4-anilinoquinoline with PDE4B inhibitory activity

In another communication, the discovery of 3-aminocarboxy-4-anilinoquinoline **8** (Figure 3) as a potent and selective PDE4 inhibitor (PDE4B pIC_{50} 8.4) is described [39]. Further structural modification of compound **8** has been carried out and the structure-activity relationship of a novel series of quinoline-3-carboxamides **9a–d** (Figure 3) at fourth, sixth, and 8-methyl compounds is described by the authors. A further compound, **9d** (GSK256066), was identified as a highly potent PDE4 inhibitor suitable for inhaled administration, which also inhibited the LPS-induced production of TNF- α from isolated human peripheral blood mononuclear cells with a pIC_{50} of 11.1, and negligible oral

bioavailability in rats. The crystal structure of GSK256066 bound to PDE4B was also obtained to 1.75 Å resolution (PDB ID: 3GWT).

By high throughput screening, tetrahydrobenzothiophene (THBT) bisamide (**10**) (Figure 4) was discovered to be a potent and modest PDE4B over the 4D-selective inhibitor (PDE4B/4D $pI_{C_{50}}$ 6.7/6.5) [40]. Authors investigated the HBT binding mode with the ligand/PDE4B catalytic domain of the available co-crystal structure (PDB ID: 3HMY) [41] to design the analogue having PDE4B selectivity over PDE4D. Furthermore, based on the binding mode at the active site of PDE4B, disubstituted-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamides **11** (Figure 4) were synthesized and evaluated for their binding affinity to the PDE4B isoenzyme. Authors disclosed the structure-activity relationship at 3-carboxy and around the tetrahydrobenzo groups. Potencies significantly reduced when the primary amide was methylated and indicated a clear requirement for the primary carboxamide at third position. Structural modification around the tetrahydrobenzo group confirmed the 4B-subtype selectivity and indicated a preference for small C6 substituents. Moreover, the maximum potency and 10-fold selectivity was observed in the compound where $R^2 = 6$ -ethyl.




Fig. 4. Structures of various congeners of 1-benzothiophene-3-carboxamides with PDE4B inhibitory activity




Fig. 5. Analogues of pyridazino[4,5-*b*]indolizine with PDE4B inhibitory activity




Fig. 6. Analogues of 1,2-dimethyl-1*H*-pyrrolo[2,3-*d*]pyridazine with PDE4B inhibitory activity

In search of new compounds to treat inflammation, the pyridazino[4,5-*b*]indolizine analogue **12a** (Figure 5) was found to possess a 23-fold selectivity for PDE4B (K_i 2.60 μM) over PDE4D [42]. In order to improve potency and selectivity, the substituted phenyl analogues **12b–g** were prepared and comparable results were obtained from a cell-based adenylyl cyclase functional assay (PDE4B, IC_{50} 13.2 μM ; PDE4D, IC_{50} >100 μM). Interestingly, the fluorine-substituted analogue **12e** was found to have high selectivity towards PDE4B compared to the derivative **12a**. In N-acetyl piperazine analogue **13** (Figure 6), the electron-withdrawing substituent on the 3-position of benzene significantly increased the PDE4B inhibitory potency (PDE4B K_i 1.90 μM). 1,2-Dimethyl-1*H*-pyrrolo[2,3-*d*]pyridazine analogues **14a–d** (Figure 6) were synthesized and evaluated for the selective affinity for PDE4B compared to PDE4D. Results revealed that -Cl and -Br substituents, respectively, at second and fourth position of the phenyl ring reduced the PDE4B affinity.

In continuation of the above work [42], two 1,2-dimethyl-1*H*-pyrrolo[2,3-*d*]pyridazine analogues, **15a** and **15b** (Figure 6) have been reported to possess greater affinity as well as selectivity for PDE4B. However, the analogue **15b** having the 3-NO₂-C₆H₅ substituent on seventh position of the pyrrolo[2,3-*d*]pyridazine ring showed poor oral bioavailability in the pharmacokinetic study. On the other hand, unsubstituted analogue **15a** exhibited an impressive 205-fold selectivity for PDE4B when compared to PDE4D.

In relation to the development of selective PDE4B inhibitors, a series of novel 1-(aryl-methyldiyne)-1,2,3,4-tetrahydro-1 λ^5 -quinolines **16a–f** (Figure 7), structurally related, respectively, to nimesulide and their 2-oxo analogues and **17a–f** (Figure 7), have been designed and synthesized using Sonogashira coupling as a key step [43]. Synthesized compounds were evaluated *in vitro* for their PDE4B inhibitory activity at 30 μM . Compounds **16c** and **17d**, having 3-nitrophenyl and 2-chlorophenyl substituents, respectively, on the alkynyl chain attached to the nitrogen of the tetrahydroquinoline ring

showed significant PDE4B inhibition (41.64 and 54.37%, respectively). Authors also presented *in silico* docking study results and interestingly, derivative **17c** showed both electrostatic and hydrophobic interactions with the PDE4B enzyme.




Fig. 7. Analogues of 1-(arylmethylidene)-1,2,3,4-tetrahydro-1λ⁵-quinoline with PDE4B inhibitory activity




Fig. 8. Analogues of pyrazolo[1,5-a]pyridine with PDE4B inhibitory activity

Further investigation established a basis for the development of potent PDE4-selective and dual PDE3/4-selective inhibitors [44]. In a separate communication [45] authors disclosed (-)-6-[7-methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone (**18**) (Figure 8) as a dual PDE3/4 inhibitor (PDE4B IC₅₀ 0.47) with potent bronchodilatory and anti-inflammatory activities and an improved therapeutic window over roflumilast in a number of *in vitro* and *in vivo* models used for pharmacological profiling. Based on the structure of compound **18** and in continuation of the above work, authors [46] disclosed a novel series of 4,4-dimethylpyrazolones **19a-h** (Figure 8) as dual PDE3/4 inhibitors. Potential bicyclic heteroaromatic replacement subunits for the pyrazolo[1,5-a]pyridine core of this series has also been undertaken and the activity of the resulting compounds is described. Synthesized compounds were evaluated to optimize the effect of substituents on seventh position of the pyrazolo[1,5-a]pyridine nucleus. Compounds **19a-h** showed promising *in vitro* PDE4B inhibition (IC₅₀ 0.16, 0.017 μM, 0.41 μM, 0.079 μM, 0.015 μM, 0.035 μM, 0.0034 μM, 0.0075 μM,

respectively). Interestingly, the 7-ethyl derivative (**19b**) was found to be 25-fold more effective as a PDE4 inhibitor than the 7-methoxy analog (**19c**), revealing that strict catechol ether is not required and indeed potentially detrimental to PDE4-inhibitory activity.

A novel series of 3,5-disubstituted-1,2,4-oxadiazoles **20a-g** (Figure 9) has been prepared and evaluated for PDE4B2 inhibitory activity [47]. Among the synthesized compounds, **20a** exhibited maximum PDE4B2 inhibition (IC_{50} 5.28 μ M). A structure-activity relationship study revealed that the substituents 3-cyclopentyloxy-4-methoxyphenyl group at third position and the cyclic ring bearing heteroatoms at fifth position of the 1,2,4-oxadiazole ring are important for activity. The molecular modeling study showed similar interactions of the 3-cyclopentyloxy-4-methoxyphenyl group compared to the piclamilast. However, the heteroatom ring was found to be slightly deviated compared to piclamilast. Compound **20a** exhibited significant analgesic and anti-inflammatory activities in the formalin-induced pain in mice and carrageenan-induced paw edema model in rats.




Fig. 9. Analogues of 3,5-disubstituted-1,2,4-oxadiazole with promising PDE4B2 inhibitory activity

Inspired by the development of multifunctional drugs, a new series of phthalazine analogues **21** and **22a-d** (Figure 10) is described [48] for the treatment of both asthma and COPD, which could target the β_2 -adrenoceptor and PDE4B₂. Synthesized compounds **21** and **22a-d** exhibited PDE4B2 IC_{50} values of 0.520, 0.280, 0.278, 0.257, and 0.251 μ M, respectively. Authors disclosed that the hexyl chain linking the hexahydrophthalazinone and *N*-[5-(2-aminoethyl)-2-hydroxyphenyl]formamide moieties (**22d**) is optimum for PDE4B2 inhibition. The synthesized compounds were also tested for guinea pig tracheal chain relaxation. Derivative (R)-(**22b**) showed significant relaxant effects on histamine-induced guinea pig tracheal chain contractions (pEC_{50} 9.3) compared to the reference drug isoprenaline (pEC_{50} 7.5).




Fig. 10. Analogues of hexahydrophthalazinone that have shown promising PDE4B2 inhibitory activity

In a similar work, PDE4B inhibitors bearing formoterol-phthalazinone hybrids were synthesized and evaluated as potent PDE4B2 inhibitors with β -agonist activity [49]. Three derivatives **23a-c** (Figure 11) exhibited potent PDE4B2 inhibition (IC_{50} 0.117 μ M, 0.118 μ M, and 0.104 μ M, respectively). These compounds also displayed moderate-to-high β_2 -adrenoceptor agonist potency on isolated guinea pig tracheal rings pre-contracted with histamine. Compound (R,R)-**23c** showed the most potent agonist activity with a pEC_{50} value of approximately 9.0. Moreover, the same compound displayed strong PDE4B2 inhibitory activity with an IC_{50} of 0.092 μ M.




Fig. 11. Formoterol-phthalazinone hybrids that have shown promising PDE4B2 inhibitory activity

Ethyl 4,5-disubstituted-4,5-dihydropyrazole-3-carboxylates **24-27** (Figure 12) were synthesized through Pd/C-Cu catalysis as a new class of PDE4B inhibitors [50]. Synthesized compounds were evaluated against the PDE4B enzyme isolated from Sf9 cells and results were compared with the reference compound rolipram, a well-known inhibitor of PDE4. All compounds showed significant inhibition (>70%) of PDE4B when tested at 30 μ M. A dose-response study was also carried out using compound **27** which showed dose-dependent inhibition of PDE4B. It is well-known that inhibition of the PDE4D subtype is linked to the emetic response [51]; hence, compounds **24-27** were tested for their PDE4B selectivity over PDE4D. Tested compounds showed 20-30% inhibition at 30 μ M indicating their approximately two-fold selectivity towards PDE4B. The *in silico* docking study result of compound **25** showed the interaction of the hydroxyl function of Tyr233 with pyrazole nitrogen, the π - π stacking interaction between the pyrazole ring and His234, coordinate interaction between the Mg^{+2} ion and the ester carbonyl function, and

coordinate interaction between the Zn^{+2} ion and pyrazole nitrogen. On the other hand, the π - π stacking interaction between pyrazole and His234 and the coordinate interaction between Mg^{++} and the ester carbonyl group was observed in compound **26**.




Fig. 12. Analogues of ethyl 4,5-disubstituted-4,5-dihydropyrazole-3-carboxylate with PDE4B inhibitory activity

Green synthesis of functionalized cyano pyridines **28a–e** (Figure 13) as novel PDE4B inhibitors has been described via the montmorillonite K-10-mediated multi-component reaction in a chemo- and regioselective manner [52]. The synthesized compounds were evaluated for their PDE4B inhibitory potency at 30 μ M using rolipram as the standard. The *in vitro* results revealed that a strong electron donating group such as OCH_3 at the para position of the benzene ring in **28a** (percentage inhibition 64.10) and **28b** (percentage inhibition 65.0) was optimum for the activity compared to other milder electron donating groups such as F or Br (**28c–e**) (percentage inhibition <45). The di- or tri- substitution on the C-4 benzene ring resulted in the loss of PDE4B inhibitory activity. *In silico* docking studies showed the binding affinities of compounds **28a** and **28c** with a docking score of -25.47 and -17.8 kcal/mol, respectively. The cyano group of compound **28c** formed H-bonding with HIS234 of the PDE4B isoenzyme. However, it was the OCH_3 group in **28a** that formed H-bonding with the Glu443 residue of PDE4B. In addition, it also showed an arene-arene interaction with the Phe446 residue.




Fig. 13. Cyano pyridine derivatives with PDE4B inhibitory activity





Fig. 14. 1,3,4-oxadiazole and 1,2,4-oxadiazole containing 1-ethyl-1*H*-pyrazolo[3,4-*b*]-pyridines with PDE4B inhibitory activity

1,3,4-oxadiazole and 1,2,4-oxadiazole containing 1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridines **29a–d** and **30a–d** (Figure 14) have been explored as potent PDE4B inhibitors [39] (pIC_{50} 8.0–8.7 and 7.8–9.4, respectively) taking into account the discovery of 4-(substituted amino)-1-alkyl-pyrazolo[3,4-*b*]pyridine-5-carboxamides as potent and selective PDE4B inhibitors [37]. The structure-activity relationship of fifth 5-position was studied [53] further. Preliminary structure-activity studies were conducted against isolated PDE4B, the predominant PDE4 subtype in inflammatory cells of interest. Results indicated that both oxadiazole isomers were tolerated at fifth position. Different oxadiazole substituents showed significant potency in each series, but unfortunately no structure-activity relationship was established. Further di-substituted and mono-substituted oxazoles **31a** and **31b** (Figure 14) were also synthesized. The di-substituted oxazole **31a** demonstrated sub-nM activity in the isolated enzyme and isolated human peripheral blood mononuclear cells (PBMC) assay and gave at least a 10-fold increase in potency over 1,3,4-oxadiazole **13c** and 1,2,4-oxadiazole **29b**. Moreover, in compound **31a**, the introduction of a second substituent showed an increase in potency in comparison to the mono-substituted oxazole **31b**.

In the year 2013, compound **32** (Figure 15) was identified as an orally active PDE4B-selective inhibitor over PDE4D both in humans (80-fold selective) and mice (29-fold selective) [54]. The therapeutic effect of compound **32** was evaluated on lipopolysaccharide (LPS) injection-induced plasma TNF- α elevation and on LPS inhalation-induced pulmonary neutrophilia in mice. The therapeutic index for TNF- α production ($TI^{TNF} = ID_{50}$ in gastric emptying/ ID_{50} in LPS injection-induced plasma TNF- α elevation) of compound **32** was larger than roflumilast (9.0 and 0.2, respectively), whereas the therapeutic index for pulmonary neutrophilia of compound **32** was comparable to roflumilast (1.0 and 0.5, respectively). Authors disclosed that the TI^{TNF} of compound **32** was not superior compared to that of roflumilast in spite of its high selectivity for PDE4B over PDE4D in mice.




Fig. 15. Structure of 7,8-dihydro-6*H*-thiopyrano[3,2-*d*]pyrimidine analogue, an orally active PDE4B-selective inhibitor

In a separate communication, 2-phenylpyrimidine **33** and 5-carbamoyl-2-phenylpyrimidine **34** derivatives (Figure 16) were reported as potent PDE4B (IC_{50} 25 nM and 200 nM, respectively) and mTNF- α (IC_{50} 390 and 690 nM, respectively) inhibitors [55]. Compounds were also evaluated *in vivo* against LPS-induced pulmonary neutrophilia in mice. In compound **34**, substitution of methyl (**35a**) (PDE4B IC_{50} 4000 nM) or methylthio (**35b**) (PDE4B IC_{50} 2000 nM) groups (Figure 16) on sixth position of the pyrimidine ring markedly reduced the PDE4B inhibitory activity. Moreover, substitution of *N*-methylacetamide (**36a**)

(PDE4B IC_{50} 8200 nM), N,N-dimethylacetamide (**36b**) (PDE4B IC_{50} 8% at 10 μ M), and N-hydroxyacetamide (**36c**) (PDE4B IC_{50} 42% at 3 μ M) groups (Figure 16) on fifth position of the pyrimidine ring resulted in a marked decrease in potency, whereas derivative **37** (Figure 16) with the *N*-(2,2-dimethylpropyl)acetamide substituent on fourth position of the phenyl ring exhibited maximum *in vitro* inhibitory activities against PDE4B (IC_{50} 8.3 nM) and TNF- α (IC_{50} 3.0 nM). The 5-carbamoyl moiety of compound **37** exhibited a water-bridged hydrogen bonding network with Asn395 and Gln443 residues in an X-ray crystallography study. In derivatives **36a–c**, substituents hindered these interactions and this may be the reason for the lowered potency. The higher potency of **37** is further supported by the lengthy neopentyl substituent which fits into the lipophilic pocket.




Fig. 16. Structure of 2-phenylpyrimidine analogues showing selective PDE4B inhibitory activity

A novel series of spirooxindoles have been synthesized in the one-pot efficient methodology using Cu-mediated 1,3-dipolar cycloaddition of azomethine ylides with dipolarophiles and evaluated for *in vitro* inhibition of PDE4B [56] using rolipram as a reference compound. The structure-activity relationship study revealed compound **38** (Figure 17) as a potent PDE4B inhibitor with >40% inhibition at 30 μ M. In the *in silico* docking result, compound **38** C=O function showed two hydrogens bonding with His278 and Met347 residues of the active site. Additionally, hydrophobic interactions with the hydrophobic clamp residue of the Q-pocket were also observed.




Fig. 17. Structure of spirooxindole that showed promising PDE4B inhibitory activity

One-pot synthesis of benzofuran fused N-heterocycles **39** and **40a–g** (Figure 18) has been achieved by AlCl_3 -mediated C–C followed by C–O bond formation between 2,3-dichloropyrazine or its derivatives and phenols. Synthesized compounds were tested *in vitro* for their PDE4B inhibitory activity [57]. Compound **39** showed significant PDE4B inhibition at 30 μM in comparison to the reference compound rolipram. Compounds possessing a substituent on the benzofuran moiety showed moderate activities and the presence of a smaller substituent was well-tolerated compared to a larger or bulky group in terms of PDE4 inhibition.





Fig. 18. Structure of benzofuran analogues that showed promising PDE4B inhibitory activity

A number of novel imidazophenoxazine-4-sulfonamides **41a–c** (Figure 19) have been designed as potential inhibitors of PDE4. Designed compounds were synthesized in a multi-step reaction process involving the construction of a 1-nitro-10H-phenoxazine ring and then fusion with an imidazole ring as the key steps [58]. Some of these compounds showed promising *in vitro* PDE4B and D inhibition when tested. Compounds bearing 2-hydroxyphenyl (**41a**), 2-bromophenyl (**41b**), and 5-bromo-2-fluorophenyl (**41c**) exhibited dose-dependent inhibition of PDE4B with IC_{50} values of 3.31 ± 0.62 , 1.23 ± 0.18 , and 0.53 ± 0.18 μM , respectively. The interaction of compound **41a** with the PDE4B was mainly contributed by H-bonding between the amino group of **41a** with His-278, H-bonding between the hydroxyl group of **41a** and Asp392, and two π – π stacking interactions between the benzimidazole moiety and His234. Similarly, the interaction of compound **41b** with the PDE4B was contributed by H-bonding between the NH_2 -group of **41b** and Thr345, as well as Asp392, π – π stacking interactions between the central 1,4-oxazine ring and Tyr233, and π – π stacking interactions between the phenyl group of **41b** and Phe446. In


compound **41c**, H-bonding between the amino group and Asp275 and π - π stacking interactions between the aromatic ring system and Tyr233, His234, and Phe446 residues of PDE4B was observed.



R= **a**: 2-OH-C₆H₄; **b**: 3-Br-C₆H₄; **c**: 5-Br-2-F-C₆H₃

(41)


Fig. 19. Novel series of imidazophenoxazine-4-sulfonamides that have shown promising PDE4B inhibitory activity



R= **a**: CF₃, n=2; **b**: CF₃, n=3; **c**: CF₃, n=4;

d: CF₃, n=5; **e**: C₂H₅, n=3; **f**: C₂H₅, n=4

(42)



(43)

Fig. 20. Novel series of N-alkylated pyridazinones that have shown selective PDE4B inhibitory activity

Yet in another publication [59], authors explored the effect of N-alkylation of the pyridazinone ring in compound **18** (Figure 8) on PDE4B inhibition and selectivity. N-alkylation of the pyridazinone ring resulted in a marked enhancement of potency against PDE4, but suppressed PDE3 inhibition. Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N-alkyl group in derivatives **42a–f** (Figure 20) facilitated both the enhancement of PDE4-inhibitory activity and the restoration of potent PDE3 inhibition. These modifications of structural changes afforded potent dual PDE3/4 inhibitors and most of the synthesized compound suppressed histamine-induced bronchoconstriction *in vivo* and exhibited promising anti-inflammatory activity *via* intratracheal administration.

The selectivity towards PDE4B increased by 23- to 350-fold in the trifluoromethyl substituted series **42a–d** (IC_{50} 0.66, 3, 0.3, 0.2 nM, respectively) compared to the lead compound **18** (PDE4B IC_{50} 70 nM), whereas the ethyl substituted derivatives **42e** and **42f** exhibited a lower PDE4B selectivity than its congeners (IC_{50} 5.9 and 1.7 nM, respectively). Considering the variations in selectivity of compounds possessing tetramethylene (**42c**) and pentamethylene (**42d**), linkers were further explored for the structure-activity relationship with 5-methyl-3,4-dihydropyridazinone and 4,4-dimethylpyrazolone subunits (**43a–g**) (Figure 20). *In vitro* screening results revealed a reduced PDE3A selectivity with moderate inhibition of PDE4B in compounds **43b** and **43d** (PDE4B IC_{50} 6 nM and 20 nM, respectively) having a fully unsaturated pyridazinone nucleus [59]. Varying the 5-methyl-3,4-dihydropyridazinone ring from fourth position in **43a** (PDE4B IC_{50} 0.3 nM) to third position in **43b** (PDE4B IC_{50} 0.5 nM) retained the selectivity for PDE4B at the cost of PDE3A selectivity. Based upon the *in vitro* results, compounds having 4,5-dihydropyridazin-3(2H)-one (**43c**, PDE4B IC_{50} 0.1 nM) and 4,4-dimethyl-1H-pyrazol-5(4H)-one (**43f**, PDE4B IC_{50} 0.5 nM) rings were found to be promising in PDE4B inhibition.




Fig. 21. Structure of benzoxazinone derivatives that have shown potent PDE4B inhibitory activity

Compound **44** (Figure 21) was discovered as a virtual hit in a docking study where the benzoxazinone moiety carbonyl function formed a H-bond with His234 of the metal binding pocket and the N-methanesulfonyl oxygen formed a H-bond with Gln443 of the Q pocket in the active site. These interactions were similar to that of the known inhibitor rolipram [60]. 2*H*-1,3-benzoxazin-4(3*H*)-one derivatives **45a-d** and **46** (Figure 21) containing respectively 1-(methylsulfonyl)-1*H*-indole or benzofuran moieties were synthesized by Pd/C–Cu-mediated coupling-cyclization. The *o*-iodoanilides or *o*-iodophenol were coupled with 3-{2-(prop-2-ynyloxy)ethyl}-2*H*-benzo[*e*][1,3]oxazin-4(3*H*)-one using 10% Pd/C–CuI–PPh₃ as the catalyst and triethylamine as the base. Synthesized compounds were tested *in vitro* for their PDE4B inhibitory potential using a cell-based cAMP reporter assay. The tested compounds exhibited potent inhibition of PDE4B at 30 μM. Compound **44** showed a five-fold increase over the control, whereas rolipram showed a nine-fold increase. In the dose-response curve, compound **44** also showed a dose-dependent increase in cAMP levels.

In search of highly selective PDE4B inhibitors, a novel series of 5,5-dioxo-7,8-dihydro-6*H*-thiopyrano[3,2-*d*]pyrimidines were synthesized and evaluated for their PDE4B subtype selectivity using human PDE4B2 and PDE4D2 full-length enzymes [61]. The molecules were optimized by varying the substituents on the pyrimidine ring and the phenyl ring present over the side chain. The *in vitro* screening of the synthesized compounds resulted in the identification of 2-(3-chloro-4-methoxyphenyl)-5,5-dioxo-7,8-dihydro-6*H*-thiopyrano[3,2-*d*]pyrimidine (**47**) (Figure 22) as a highly selective PDE4B inhibitor, which showed PDE4B inhibitory activity with an IC₅₀ value of 3.0 nM and 433-fold PDE4B selectivity over PDE4D.




Fig. 22. Structure of the 5,5-dioxo-7,8-dihydro-6*H*-thiopyrano[3,2-*d*]pyrimidine analogue that has shown highly selective PDE4B inhibition

Selective PDE4 inhibitors exhibit antiproliferative activity against T-cells and B-cells and this finding helped researchers to investigate the selective PDE4 inhibitors as novel anticancer agents. This was further supported by the antiproliferative activity of PDE4 inhibitors against murine carcinoma cells [62]. PDE4 inhibitor rolipram induced cell cycle arrest and apoptosis [63], and overexpression of PDE4B resulted in diffuse large cell lymphoma (DLBCL); a fatal malignancy indicating that PDE4B inhibitors could be useful anticancer agents [64]. Moreover, PDE4B selective inhibitors were reported for selective apoptosis in malignant cells without affecting the normal cells. Based on these facts, novel PDE4B inhibitors were developed and screened for anticancer activity [65].

In the year 2013, novel *N*-[(1-substituted-1*H*-1,2,3-triazol-4-yl)methyl]-*N*-2,2,4-trimethyl-7-phenoxy-1,2-dihydroquinolinemethanesulfonamides **48a–e** (Figure 23) were synthesized as selective PDE4B inhibitors. The reaction was carried out in aqueous DMF *via* a multi-step sequence consisting of copper-catalyzed azide-alkyne cycloaddition (CuAAC) as the key step [66]. The compounds were evaluated *in vitro* for their cytotoxic activity using the lung adenocarcinoma epithelial cell line (A549), prostate cancer cell line (DU145), cervical cancer cell line (HeLa), and hepatocellular liver carcinoma cell line (HepG2) in an MTT assay. Among the synthesized inhibitors, **48a** and **48b** showed promising activity against the human lung cancer cell line (A549) with an IC_{50} of 8–9 μ M. Although compounds **48b**, **48d**, and **48e** were identified as potent PDE4B inhibitors, they showed no cytotoxic activity towards the tested cancer cell lines. The docking results of the synthesized compounds revealed a high binding affinity of compound **48d** with 1XMY (PBD ID). Hydrogen bonding with HIE-234 and π - π stacking interactions with PHE446 residues were also observed.




Fig. 23. Structure of 1,2-dihydroquinolinemethanesulfonamide analogues that have shown potent PDE4B inhibition and anticancer activity





Fig. 24. Structure of 1,2,4-triazole analogues that have PDE4B inhibition and anticancer activity

The novel nimesulide-based new class of triazole derivatives **49a–d** (Figure 24) were synthesized as PDE4B inhibitors [67]. The synthesized compounds were tested against cancer cells, keeping in view the reported anticancer activity of nimesulide [68] and the anti-inflammatory activity of 1,2,4-triazoles [69]. Some of the synthesized compounds exhibited significant *in vitro* PDE4B inhibitory properties with >50% inhibition at 30 μM . Moreover, results were also supported by the docking studies. The *in vitro* anticancer activity was evaluated using the HCT-15 human colon cancer cell lines with doxorubicin [IC_{50} 50 $\mu\text{g}/\text{mL}$, (0.09 μM)], an anthracyclin antibiotic as the reference compound. Two of the synthesized compounds **49c** and **49d** exhibited IC_{50} values in the range 21–22 $\mu\text{g}/\text{mL}$. Docking results of synthesized compounds revealed similar interactions with Gln443 as that of rolipram. Apart from Gln443, compound **49a** also exhibited interactions with His234 and His278, whereas compound **49b** and **49c** showed binding affinity for Asn283.

During cardiac action potential, Ca^{2+} influx through the sarcolemma L-type Ca^{2+} channels (LTCC) triggers Ca^{2+} release from ryanodine receptor 2 located in the sarcoplasmic reticulum; this results in elevated Ca^{2+} throughout the cell leading to contraction of the myocardium. PDE4 is one of the main PDEs expressed in the heart. PDE4 becomes predominantly active upon β -adrenergic receptor stimulation and regulates LTCC and cAMP levels in cardiomyocytes [70–75]. In PDE4B-deficient mice, increased expression of the β -adrenoreceptor along with LTCC was observed leading to elevated intracellular Ca^{2+} and cell contraction [76].



$\text{R}^1 = \text{a: } 4\text{-Cl-C}_6\text{H}_4; \text{ b: } 3\text{-F-C}_6\text{H}_4; \text{ c: } 3\text{-Cl-C}_6\text{H}_4;$
 $\text{d: indaloyl; e: } 3\text{-NO}_2\text{-C}_6\text{H}_4; \text{ f: CH}_2\text{C}_6\text{H}_4;$
 $\text{g: naphthyl; R}^2 = 3,4\text{-(OCH}_3)_2\text{-CH}_2\text{C}_6\text{H}_3$

(50)

Fig. 25. Structure of 1,4-dihydropyridine analogues that have Ca^{2+} channel blocking and PDE4B inhibitory activities

In another study, a novel series of 1,4-dihydropyridine-based PDE4B inhibitors were synthesized [77] and evaluated for their *in vitro* Ca^{2+} channel blocking and PDE4B inhibitory activities. Compounds **50a–g** (Figure 25) exhibited >80% inhibition of PDE4B. Among the synthesized inhibitors, **50d**, having an indaloyl moiety, exhibited significant selectivity towards PDE4B with a docking score of -8.1 kcal/mol. The *in silico* docking result of compound **50d** supported the reason for the selectivity, where the indole moiety exists in two different orientations in PDE4D, and in both cases, it makes a stronger hydrogen bond with Glu396 or Glu505 residues of PDE4D, while its orientation in PDE4B is completely different than that in PDE4D. The dimethoxy group of **50d** interacted with the metal atoms in PDE4B, while the indole moiety was shown to be H-bonded with the Ser442 backbone.

In recent research [78], authors disclosed that PDE4B selectivity can be achieved by the capture of a C-terminal regulatory helix, known as CR3 (control region 3), across the active site in a conformation that closes access by cAMP. PDE4B selectivity is driven by a single amino acid polymorphism in CR3 (Leu674 in PDE4B1 versus Gln594 in PDE4D). A new co-crystal structure with a bound ligand was developed which provided a guide map for the design of PDE4B-selective anti-inflammatory drugs. The comparative binding modes of the 2-arylpyrimidine derivative with PDE4D (PDB: 3G58), NVW-PDE4B (PDB: 3W5E), and OCP-PDE4B (PDB: 3KKT) structures showed that small molecules can interact with different residues of the CR3 helix resulting in multiple closed conformations. The study highlighted the significance of (PDE4B Leu674/PDE4DGln594 and PDE4B Met675/PDE4D Thr595) that is essential to engage the ligand and/or catalytic domain.

Conclusion

Advancements in PDE4B selective-targeted therapies have shown promise in recent years for the treatment of inflammation, chronic obstructive pulmonary disorders, cancers, and myocardium contractility disorder. After the development of the prototypic PDE4 inhibitor rolipram, more selective inhibitors targeting the PDE4B isozyme have been widely investigated. However, the biological activity of this class of compounds deserves further investigation. This is evident when inflammatory diseases are considered. Although the research on this subject is incipient, the number of reports disclosing the effects of PDE4B inhibitors on TNF- α production and Ca²⁺ channel blockage has recently been increasing. PDE4B selective inhibitors have been shown to be promising, which calls for the design of more efficient anti-inflammatory, anticancer, and cardio-protective agents. Although some patterns appear relating the structure and the pharmacological field, this also should be considered when designing new selective PDE4B inhibitors.

Acknowledgement

The authors are grateful to the Science and Engineering Research Board (SERB), Government of India for the financial support (No. SR/S0/HS-0264/2012).

Abbreviations

PDE	phosphodiesterases;
cAMP	cyclic adenosine monophosphate;
cGMP	cyclic guanosine monophosphate;
pIC ₅₀	negative logarithm of the half maximal inhibitory concentration;
COPD	chronic obstructive pulmonary disease;
TNF	tumor necrosis factor;
nM	nanomol;
PDB	protein data bank;
IC ₅₀	half maximal inhibitory concentration;
pEC ₅₀	negative logarithm of half maximal effective concentration;
μ M	micromol;
LPS	lipopolysaccharide;

MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
LTCC	sarcolemma L-type Ca ²⁺ channels;o
SAR	structure-activity relationship;
CR3	control region 3;
NVW	<i>N-tert-butyl-2-{4-[(5,5-dioxido-2-phenyl-7,8-dihydro-6H-thiopyrano[3,2-d]-pyrimidin-4-yl)amino]phenyl}acetamide;</i>
OCP	5-{3-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl}-tetrahydropyrimidin-2(1H)-one;

Authors' Statement

Competing Interests

The authors declare no conflict of interest.

References

- [1] O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). *Trends Pharmacol Sci.* 2004; 25: 158–163. <http://dx.doi.org/10.1016/j.tips.2004.01.003>
- [2] Kaness SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. *Neuroscience.* 2007; 144: 239–246. <http://dx.doi.org/10.1016/j.neuroscience.2006.09.026>
- [3] Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. *Inflamm Allergy Drug Targets.* 2007; 6: 17-26. <http://dx.doi.org/10.2174/187152807780077318>
- [4] Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. *Immunopharmacology.* 2000; 47: 127–162. [http://dx.doi.org/10.1016/S0162-3109\(00\)00185-5](http://dx.doi.org/10.1016/S0162-3109(00)00185-5)
- [5] Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. *J Biol Chem.* 2003; 278: 5493–5496. <http://dx.doi.org/10.1074/jbc.R200029200>
- [6] Wang P, Ohleth KM, Wu P, Billah MM, Egan RW. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. *Mol Pharmacol.* 1999; 56: 170–174. <http://www.ncbi.nlm.nih.gov/pubmed/10385698>
- [7] Xu RX, Rocque WJ, Lambert MH, Vanderwall DE, Luther MA, Nolte RT. Crystal Structures of the Catalytic Domain of Phosphodiesterase 4B Complexed with AMP, 8-Br-AMP, and Rolipram. *J Mol Biol.* 2004; 337: 355–365. <http://dx.doi.org/10.1016/j.jmb.2004.01.040>

- [8] Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, Nolte RT. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. *Science*. 2000; 288: 1822–1825. <http://dx.doi.org/10.1126/science.288.5472.1822>
- [9] Sanz MJ, Cortijo J, Morcillo EJ. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. *Pharmacol Ther*. 2005;106: 269–297. <http://dx.doi.org/10.1016/j.pharmthera.2004.12.001>
- [10] Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. *Lancet*. 2005; 8-14: 365: 167–175. [http://dx.doi.org/10.1016/S0140-6736\(05\)17708-3](http://dx.doi.org/10.1016/S0140-6736(05)17708-3)
- [11] Fan CK. Phosphodiesterase inhibitors in airways disease. *Eur J Pharmacol*. 2006; 533: 110–117. <http://dx.doi.org/10.1016/j.ejphar.2005.12.059>
- [12] Keshavarzian A, Mutlu E, GuzmanJP, Forsyth C, Banan A. Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease. *Expert Opin Investig Drugs*. 2007; 16: 1489–1506. <http://dx.doi.org/10.1517/13543784.16.9.1489>
- [13] Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. *Curr Opin Pharmacol*. 2012; 12: 275–286. <http://dx.doi.org/10.1016/j.coph.2012.02.016>
- [14] Jin SL, Ding SL, Lin SC. Phosphodiesterase 4 and Its Inhibitors in Inflammatory Diseases. *Chang Gung Med J*. 2012; 35: 197–210. <http://www.ncbi.nlm.nih.gov/pubmed/22735051>
- [15] Wittmann M, Helliwell PS. Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases. *Dermatol Therap*. 2013; 3: 1–15. <http://dx.doi.org/10.1007/s13555-013-0023-0>
- [16] Kumar N, Goldminz AM, Kim N, Gottlieb AB. Phosphodiesterase 4-targeted treatments for autoimmune diseases. *BMC Medicine*. 2013; 11: 96. <http://dx.doi.org/10.1186/1741-7015-11-96>
- [17] Sutherland EW, Rall TW. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. *J Biol Chem*. 1958; 232: 1077–1091. <http://www.ncbi.nlm.nih.gov/pubmed/13549488>
- [18] Schett G, Sloan VS, Stevens RM, Schafer P. Apremilast: A Novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. *Ther Adv Musculoskelet Dis*. 2010; 2: 271–278. <http://dx.doi.org/10.1177/1759720X10381432>
- [19] Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. *Handbook Exp Pharmacol*. 2011; 204: 391–414. http://dx.doi.org/10.1007/978-3-642-17969-3_17

- [20] Uretsky BF, Generalovich T, Reddy PS, Spangenberg RB, Follansbee WP. The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure. *Circulation*. 1983; 67: 823–828.
<http://www.ncbi.nlm.nih.gov/pubmed/6218939>
- [21] Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. *Am J Respir Crit Care Med*. 1998; 157: 351–370.
<http://dx.doi.org/10.1164/ajrccm.157.2.9708012>
- [22] Siuciak JA, Chapin DS, McCarthy SA, Martin AN. Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. *Psychopharmacology (Berl)*. 2007; 192: 415–424.
<http://dx.doi.org/10.1007/s00213-007-0727-x>
- [23] Siuciak JA, McCarthy SA, Chapin DS, Martin AN. Behavioural and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. *Psychopharmacology (Berl)*. 2008; 197: 115–126.
<http://dx.doi.org/10.1007/s00213-007-1014-6>
- [24] Cherry JA, Davis RL. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. *J Comp Neurol*. 1999; 407: 287–301.
[http://dx.doi.org/10.1002/\(SICI\)1096-9861\(19990503\)407:2%3C287::AID-CNE9%3E3.0.CO;2-R](http://dx.doi.org/10.1002/(SICI)1096-9861(19990503)407:2%3C287::AID-CNE9%3E3.0.CO;2-R)
- [25] Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, Malloy MP, Chubb JE, Huston E, Baillie GS, Thomson PA, Hill EV, Brandon NJ, Rain JC, Camargo LM, Whiting PJ, Houslay MD, Blackwood DH, Muir WJ, Porteous DJ. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signalling. *Science*. 2005; 310: 1187–1191.
<http://dx.doi.org/10.1126/science.1112915>
- [26] Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L, Dlaboga D, Jin SL, Conti M, O'Donnell JM. Anxiogenic like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). *Neuropsychopharmacology*. 2008; 33: 1611–1623.
<http://dx.doi.org/10.1038/sj.npp.1301537>
- [27] Torres PS, Miro X, Palacios JM, Cortes R, Puigdomenech P, Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by *in-Situ* hybridization histochemistry and [3H]rolipram binding autoradiography. Comparison with monkey and rat brain. *J Chem Neuroanat*. 2000; 20: 349–374.
[http://dx.doi.org/10.1016/S0891-0618\(00\)00097-1](http://dx.doi.org/10.1016/S0891-0618(00)00097-1)
- [28] Lamontagne S, Meadows E, Luk P, Normandin D, Muise E, Bou-let L, Pon DJ, Robichaud A, Robertson GS, Metters KM, Nantel F. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. *Brain Res*. 2001; 920: 84–96.
[http://dx.doi.org/10.1016/S0006-8993\(01\)03023-2](http://dx.doi.org/10.1016/S0006-8993(01)03023-2)
- [29] Ariumi H, Saito R, Nago S, Hyakusoku M, Takano Y, Kamiya H. The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis. *Neurosci Lett*. 2000; 286: 123–126.
[http://dx.doi.org/10.1016/S0304-3940\(00\)01113-7](http://dx.doi.org/10.1016/S0304-3940(00)01113-7)

- [30] Heaslip RJ; Evans DY.
Emetic, central nervous system, and pulmonary activities of rolipram in the dog.
Eur J Pharmacol. 1995; 286: 281–290.
[http://dx.doi.org/10.1016/0014-2999\(95\)00457-2](http://dx.doi.org/10.1016/0014-2999(95)00457-2)
- [31] Yuasa K, Kanoh Y, Okumura K, Omori K.
Genomic organization of the human phosphodiesterase PDE11A gene. Evolutionary relatedness with other PDEs containing GAF domains.
Eur J Biochem. 2001; 268: 168–178.
<http://dx.doi.org/10.1046/j.1432-1327.2001.01866.x>
- [32] Jin SL, Conti M.
Induction of the cyclic nucleotide Phosphodiesterase PDE4B is essential for LPS-activated TNF- α response.
Proc Natl Acad Sci U S A. 2002; 99: 7628–7633.
<http://dx.doi.org/10.1073/pnas.122041599>
- [33] Prabha NI, Bremer R, Gillette S, Chao H, Nepsi M, Mamo S, Zhang C, Artis DR, Lee B, Zuckerman R.
PDE4B inhibitors.
US patent 7605168B2, Oct., 2009. Application No. 11/219635, Sept. 2005.
- [34] Prabha NI, Cho, Hanna C, Bruce E, Sam G, Dean RA, Chao RZ.
PDE4B inhibitors and uses therefor.
US Patent 7585859B2, Sept. 2009. Application No. 11/123893, May, 2005.
- [35] Prabha NI, England B, Gillette S, Artis DR, Zuckerman R, Zhang C, Chao RZ.
PDE4B inhibitors and uses therefor.
US Patent 8470821, June 2013. Application No. 12/506222, July, 2009.
- [36] Allen DG, Coe DM, Cook CM, Dowle MD, David Edlin CD, Hamblin JN, Johnson MR, Jones PS, Knowles RG, Lindvall MK, Mitchell CJ, Redgrave AJ, Trivedi N, Ward P.
- [37] Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors.
WO2004024728 A3, Oct 21, 2004; Application No. PCT/EP2003/011814, Sep. 12, 2003.
- [38] Hamblin JN, Angell TDR, Ballantine SP, Cook CM, Cooper AWJ, Dawson J, Delves CJ, Jhones PS, Lindvall M, Lucas FS, Mitchell CJ, Neu MY, Ranshaw LE, Solanke YE, Somers DO, Wiseman JO.
Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.
Bioorg Med Chem Lett. 2008; 18: 4237–4241.
<http://dx.doi.org/10.1016/j.bmcl.2008.05.052>
- [39] Naganuma K, Omura A, Maekawara N, Saitoh M, Ohkawa N, Kubota T, Nagumo H, Kodama T, Takemura M, Ohtsuka Y, Nakamura J, Tsujita R, Kawasaki K, Yokoi H, Kawanishi M.
Discovery of selective PDE4B inhibitors.
Bioorg Med Chem Lett. 2009; 19: 3174–3176.
<http://dx.doi.org/10.1016/j.bmcl.2009.04.121>
- [40] Woodrow MD, Ballantine SP, Barker MD, Clarke BJ, Dawson J, Dean TW, Delves CJ, Evans B, Gough SL, Guntrip SB, Holman S, Holmes DS, Kranz M, Lindvaal MK, Lucas FS, Neu M, Ranshaw LE, Solanke YE, Somers DO, Ward P, Wiseman JO.
Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Bioorg Med Chem Lett. 2009; 19: 5261–5265.
<http://dx.doi.org/10.1016/j.bmcl.2009.04.012>
- [41] Kranz M, Wall M, Evans B, Miah A, Ballantine S, Delves C, Dombroski B, Gross J, Schneck J, Villa JP, Neu M, Somers DO.
Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode.
Bioorg Med Chem. 2009; 17: 5336–5341.
<http://dx.doi.org/10.1016/j.bmc.2009.03.061>

- [42] Zhang KYJ, Card GL, Suzuki Y, Artis DR, Fong D, Gillette S, Hsieh D, Neiman J, West BL, Zhang C, Milburn MV, Kim SH, Schlessinger J, Bollag G. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. *Mol Cell*. 2004; 15: 279–286. <http://dx.doi.org/10.1016/j.molcel.2004.07.005>
- [43] Donnell AF, Dollings PJ, Butera JA, Dietrich AJ, Lipinski KK, Ghavami A, Hirst WD. Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors. *Bioorg Med Chem Lett*. 2010; 20: 2163–2167. <http://dx.doi.org/10.1016/j.bmcl.2010.02.044>
- [44] Pal S, Durgadas S, Nallapati SB, Mukkanti K, Kapavarapu R, Meda CL, Parsa KVL, Pal M. Novel 1-alkynyl substituted 1,2-dihydroquinoline derivatives from nimesulide (and their 2-oxo analogues): A new strategy to identify inhibitors of PDE4B. *Bioorg Med Chem Lett*. 2011; 21: 6573–6576. <http://dx.doi.org/10.1016/j.bmcl.2011.08.033>
- [45] Allcock RW, Blakli H, Jiang Z, Johnston KA, Morgan KM, Rosair GM, Iwase K, Kohno Y, Adams DR. Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast. *Bioorg Med Chem Lett*. 2011; 21: 3307–3312. <http://dx.doi.org/10.1016/j.bmcl.2011.04.021>
- [46] Ochiai K, Ando N, Iwase K, Kishi T, Fukuchi K, Ohinata A, Zushi H, Yasue T, Adams DR, Kohno Y. Phosphodiesterase inhibitors. Part 2: Design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity. *Bioorg Med Chem Lett*. 2011; 21: 5451–5456. <http://dx.doi.org/10.1016/j.bmcl.2011.06.118>
- [47] Ochiai K, Takita S, Eiraku T, Kojima A, Iwase K, Kishi T, Fukuchi K, Yasue T, Adams DR, Allcock RW, Jiang Z, Kohno Y. Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity. *Bioorg Med Chem*. 2012; 20: 1644–1658. <http://dx.doi.org/10.1016/j.bmc.2012.01.033>
- [48] Kumar D, Patel G, Vijaykrishnan L, Dastidar SG, Ray A. Design and Synthesis of 3,5-Disubstituted-1,2,4-Oxadiazoles as Potent Inhibitors of Phosphodiesterase 4B2. *Chem Biol Drug Des*. 2012; 79: 810–818. <http://dx.doi.org/10.1111/j.1747-0285.2011.01304>
- [49] Shan WJ, Huang L, Zhou Q, Jiang HL, Luo ZH, Lai KF, Li XS. Dual β 2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD. *Bioorg Med Chem Lett*. 2012; 22: 1523–1526. <http://dx.doi.org/10.1016/j.bmcl.2012.01.013>
- [50] Huang L, Shan W, Zhou Q, Xie J, Lai K, Li X. Design, synthesis and evaluation of dual pharmacology β 2-adrenoceptor agonists and PDE4 inhibitors. *Bioorg Med Chem Lett*. 2014; 24: 249–253. <http://dx.doi.org/10.1016/j.bmcl.2013.11.028>
- [51] Gorja DR, Kumar SK, Kandale A, Meda CL, Parsa KV, Mukkanti K, Pal M. Design and synthesis of 4-alkynyl pyrazoles as inhibitors of PDE4: A practical access via Pd/C-Cu catalysis. *Bioorg Med Chem Lett*. 2012; 22: 2480–2487. <http://dx.doi.org/10.1016/j.bmcl.2012.02.008>

- [52] Robichaud A, Stamatiou PB, Catherine Jin SL, Lachance N, Mac Donald D, Laliberte F, Liu S, Huang Z, Conti M, Chan CC. Deletion of Phosphodiesterase4D in mice shortens α_2 -adrenoreceptor mediated anesthesia, a behavioural correlate to emesis. *J Clin Invest.* 2002; 110: 1045–1052. <http://dx.doi.org/10.1172/JCI15506>
- [53] Reddy TR, Reddy GR, Reddy LS, Jamula S, Lingappa Y, Kapavarapu R, Meda CLT, Parsa KVL, Pal M. Montmorillonite K-10 mediated green synthesis of cyano pyridines: Their evaluation as potential inhibitors of PDE4. *Eur J Med Chem.* 2012; 48: 265–274. <http://dx.doi.org/10.1016/j.ejmech.2011.12.024>
- [54] Mitchell CJ, Ballantine SP, Coe DM, Cook CM, Delves CJ, Dowle MD, Edlin CD, Hamblin JN, Holman S, Johnson MR, Jones PS, Keeling SE, Kranz M, Lindvall M, Lucas FS, Neu M, Solanke YE, Somers DO, Trivedi NA, Wiseman JO. Pyrazolopyridines as potent PDE4B inhibitors: 5-Heterocycle SAR. *Bioorg Med Chem Lett.* 2010; 20: 5803–5806. <http://dx.doi.org/10.1016/j.bmcl.2010.07.136>
- [55] Suzuki O, Mizukami K, Etori M, Sogawa Y, Takagi N, Tsuchida H, Morimoto K, Goto T, Yoshino T, Mikkaichi T, Hirahara K, Nakamura S, Maeda H. Evaluation of the Therapeutic Index of a Novel Phosphodiesterase 4B-Selective Inhibitor Over Phosphodiesterase 4D in Mice. *J Pharmacol Sci.* 2013; 123: 219–226. <http://dx.doi.org/10.1254/jphs.13103FP>
- [56] Goto T, Yoshino T, Mizukami K, Hirahara K, Suzuki O, Sogawa Y, Takahashi T, Mikkaichi T, Nakao N, Takahashi M, Hasegawa M, Sasaki S. Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors. *Bioorg Med Chem.* 2013; 21: 7025–7037. <http://dx.doi.org/10.1016/j.bmc.2013.09.013>
- [57] Singh SN, Regati S, Paul AK, Layek M, Jayaprakash S, Reddy VK, Deora GS, Mukherjee S, Pal M. Cu-mediated 1,3-dipolar cycloaddition of azomethineylides with dipolarophiles: a faster access to spirooxindoles of potential Pharmacological interest. *Tetrahedron Lett.* 2013; 54: 5448–5452. <http://dx.doi.org/10.1016/j.tetlet.2013.07.126>
- [58] Kumar SK, Adepur R, Kapavarapu R, Rambabu D, Krishna RG, Reddy MC, Priya KK, Parsa KVL, Pal M. $AlCl_3$ induced C-arylation/cyclization in a single pot: a new route to benzofuran fused N-heterocycles of pharmacological interest. *Tetrahedron Lett.* 2012; 53: 1134–1138. <http://dx.doi.org/10.1016/j.tetlet.2011.12.096>
- [59] Reddy SV, Rao GM, Kumar BV, Meda CLT, Deora GS, Kumar KS, Parsa KVL, Pal M. Novel imidazophenoxazine-4-sulfonamides: Their synthesis and evaluation as potential inhibitors of PDE4. *Bioorg Med Chem* 2013; 21: 1952–1963. <http://dx.doi.org/10.1016/j.bmc.2013.01.023>
- [60] Ochiai K, Takita S, Kojima A, Eiraku T, Iwase K, Kishi T, Ohinata A, Yageta Y, Yasue T, Adams DR, Yasushi Kohno Y. Phosphodiesterase inhibitors. Part 5: Hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. *Bioorg Med Chem Lett.* 2013; 23: 375–381. <http://dx.doi.org/10.1016/j.bmcl.2012.08.121>

- [61] Rao RM, Luther BJ, Rani CS, Suresh N, Kapavarapu R, Parsa KV, Rao MV, Pal M. Synthesis of 2H-1,3-benzoxazin-4(3H)-one derivatives containing indole moiety: Their in vitro evaluation against PDE4B. *Bioorg Med Chem Lett.* 2014; 24: 1166–1171. <http://dx.doi.org/10.1016/j.bmcl.2013.12.117>
- [62] Goto T, Shiina A, Murata T, Tomii M, Yamazaki T, Yoshida K, Yoshino T, Suzuki O, Sogawa Y, Mizukami K, Takagi N, Yoshitomi T, Etori M, Tsuchida H, Mikkaichi T, Nakao N, Takahashi M, Takahashi H, Sasaki S. Identification of the 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives as highly selective PDE4B inhibitors. *Bioorg Med Chem Lett.* 2014; 24: 893–899. <http://dx.doi.org/10.1016/j.bmcl.2013.12.076>
- [63] Marko D, Romanakis K, Zankl H, Fürstenberger G, Steinbauer B, Eisenbrand G. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their non-malignant counterparts. *Cell Biochem Biophys.* 1998; 28: 75–101. <http://dx.doi.org/10.1007/BF02737806>
- [64] Ogawa R, Streiff MB, Bugayenko A, Kato GJ. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21 (WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. *Blood.* 2002; 99: 3390–3397. <http://www.ncbi.nlm.nih.gov/pubmed/11964308>
- [65] Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, Bollag G, Shipp MA, Aguiar RC. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT dependent apoptosis in diffuse large B-cell lymphoma. *Blood.* 2005; 105: 308–316. <http://www.ncbi.nlm.nih.gov/pubmed/15331441>
- [66] Mentz F, Mossalayi MD, Ouaz F, Baudet S, Issaly F, Ktorza S, Semichon M, Binet JL, Merle-Beral H. Theophylline synergizes with chlorambucil in inducing apoptosis of chronic B-lymphocytic leukemia cells. *Blood.* 1996; 88: 2172–2182. <http://www.ncbi.nlm.nih.gov/pubmed/8822937>
- [67] Praveena KSS, Durgadas S, Suresh Babu N, Akkenapally S, Ganesh Kumar C, Deora GS, Murthy NY, Mukkanti K, Pal S. Synthesis of 2,2,4-trimethyl-1,2-dihydroquinolinyI substituted 1,2,3-triazole derivatives: Their evaluation as potential PDE 4B inhibitors possessing cytotoxic properties against cancer cells. *Bioorg Chem.* 2014; 53: 8–14. <http://dx.doi.org/10.1016/j.bioorg.2013.12.002>
- [68] Mareddy J, Nallapati SB, Anireddy J, Devi YP, Mangamoori LN, Kapavarapu R, Pal S. Synthesis and biological evaluation of nimesulide based new class of triazole derivatives as potential PDE4B inhibitors against cancer cells. *Bioorg Med Chem Lett.* 2013; 23: 6721–6727. <http://dx.doi.org/10.1016/j.bmcl.2013.10.035>
- [69] Chen B, Su B, Chen S. A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms. *Biochem Pharmacol.* 2009; 77: 1787–1794. <http://dx.doi.org/10.1016/j.bcp.2009.03.015>
- [70] Shafi S, Alam MM, Mulakayala N, Mulakayala C, Vanaja G, Kalle AM, Pallu R, Alam MS. Synthesis of novel 2-mercaptobenzothiazole and 1,2,3-triazole based bis-heterocycles: Their anti-inflammatory and anti-nociceptive activities. *Eur J Med Chem.* 2012; 49: 324–333. <http://dx.doi.org/10.1016/j.ejmech.2012.01.032>

- [71] Rochais F, Abi-Gerges A, Horner K, Lefebvre F, Cooper DM, Conti M, Fischmeister R, Vandecasteele G.
A specific pattern of phosphodiesterases controls the cAMP signals generated by different G-coupled receptors in adult rat ventricular myocytes.
Circ Res. 2006; 98: 1081–1088.
<http://dx.doi.org/10.1161/01.RES.0000218493.09370.8e>
- [72] Rochais F, Vandecasteele G, Lefebvre F, Lugnier C, Lum H, Mazet JL, Cooper DM, Fischmeister R.
Negative feedback exerted by PKA and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes. An in vivo study using adenovirus-mediated expression of CNG channels.
J Biol Chem. 2004; 279: 52095–52105.
<http://dx.doi.org/10.1074/jbc.M405697200>
- [73] Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T, Houslay MD, Zaccolo M.
Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases.
Circ Res. 2004; 95: 67–75.
<http://www.ncbi.nlm.nih.gov/pubmed/15178638>
- [74] Xiang Y, Naro F, Zoudilova M, Jin SL, Conti M, Kobilka B.
Phosphodiesterase 4D is required for β adrenoceptor subtype-specific signaling in cardiac myocytes.
Proc Natl Acad Sci U S A. 2005; 102: 909–914.
<http://dx.doi.org/10.1073/pnas.0405263102>
- [75] Leroy J, Abi-Gerges A, Nikolaev VO, Richter W, Lechene P, Mazet JL, Conti M, Fischmeister R, Vandecasteele G.
Spatiotemporal dynamics of β -adrenergic cAMP signals and L-type Ca^{2+} channel regulation in adult rat ventricular myocytes: Role of phosphodiesterases.
Circ Res. 2008; 102: 1091–1100.
<http://dx.doi.org/10.1161/CIRCRESAHA.107.167817>
- [76] Nikolaev VO, Bunemann M, Schmitteckert E, Lohse MJ, Engelhardt S.
Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching β -adrenergic but locally confined β -2 adrenergic receptor-mediated signaling.
Circ Res. 2006; 99: 1084–1091.
<http://dx.doi.org/10.1161/01.RES.0000250046.69918.d5>
- [77] Leroy J, Richter W, Mika D, Castro LRV, Abi-Gerges A, Xie M, Scheitrum C, Lefebvre F, Schittl J, Mateo P, Westenbroek R, Catterall WA, Charpentier F, Conti M, Fischmeister R, Vandecasteele G.
Phosphodiesterase 4B in the cardiac L-type Ca^{2+} channel complex regulates Ca^{2+} current and protects against ventricular arrhythmias in mice.
J Clin Invest. 2011; 121: 2651–2661.
<http://dx.doi.org/10.1172/JCI44747>
- [78] Poondra RR, Nallamelli RV, Meda CL, Srinivas BN, Grover A, Muttathathula J, Voleti SR, Sridhar B, Pal M, Parsa KV.
Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors.
MedChem Lett. 2013; 23: 1104–1109.
<http://dx.doi.org/10.1016/j.bmcl.2012.11.121>
- [79] Fox D 3rd, Burgin AB, Gurney ME.
Structural basis for the design of selective phosphodiesterase 4B inhibitors.
Cell Signal. 2014; 26: 657–663.
<http://dx.doi.org/10.1016/j.cellsig.2013.12.003>